共 34 条
- [34] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 40 - 51